All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-05-20T14:32:24.000Z

(177)Lu lilotomab satetraxetan receives positive opinion for orphan drug designation from EMA for MZL

May 20, 2020
Share:

Bookmark this article

On May 14, 2020, 177Lu lilotomab satetraxetan received a positive opinion from the European Medicines Agency for an orphan drug designation application for the treatment of marginal zone lymphoma (MZL). The adoption of the positive opinion by the European Commission is expected to occur shortly.1

177Lu lilotomab satetraxetan is a next generation β-particle emitting radioimmunoconjugate that sensitizes and upregulates CD37+ B-cell cancer cells before treatment with CD20 immunotherapy. Particularly, it has been shown to act synergistically with rituximab.2

The positive opinion was based on positive data from the LYMRIT-37-01 phase I/IIa (NCT01796171) trial in patients with relapsed indolent non-Hodgkin lymphoma. In the MZL patient arm (n = 9; heavily pretreated patients with advanced disease), the overall response rate was 78%, and 44% of patients achieved a complete response. Data from this trial were encouraging as a once-only administration of 177Lu lilotomab satetraxetan resulted in the highest response rate of any patient subpopulation in this trial.1

177Lu lilotomab satetraxetan has previously been granted fast-track designation in the US for the treatment of patients with relapsed or refractory follicular lymphoma after ≥ 2 prior systemic therapies.3

  1. PR Newswire. Nordic Nanovector's Betalutin® receives positive opinion for orphan drug designation from EMA for marginal zone lymphoma (MZL). https://www.prnewswire.co.uk/news-releases/nordic-nanovector-s-betalutin-r-receives-positive-opinion-for-orphan-drug-designation-from-ema-for-marginal-zone-lymphoma-mzl--823693112.html. Published May 14, 2020. Accessed May 18, 2020.
  2. Malenge MM, Patzke S, Ree AH,  et al. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma. J Nucl Med. 2020. DOI: 10.2967/jnumed.119.237230
  3. PR Newswire. Nordic Nanovector announces Betalutin® has been granted fast track designation in the US for follicular lymphoma. https://www.prnewswire.com/news-releases/nordic-nanovector-announces-betalutin-has-been-granted-fast-track-designation-in-the-us-for-follicular-lymphoma-300664612.html. Published Jun 12, 2018. Accessed May 18, 2020.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox